Evidence map›Paper›PMID 26749441›Full record

ArticleCell host & microbe2016

High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission.

David M Plouffe, Melanie Wree, Alan Y Du, Stephan Meister, Fengwu Li, Kailash Patra, Aristea Lubar, Shinji L Okitsu, Erika L Flannery, Nobutaka Kato and 10 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Onametostat, a PfPRMT5 inhibitor, exhibits antimalarial activity toAntimicrobial agents and chemotherapy · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways inbioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

David M PlouffeThe Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA.
Melanie WreeDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Alan Y DuDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Stephan MeisterDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Fengwu LiDivision of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Kailash PatraDivision of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Aristea LubarDivision of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Shinji L OkitsuDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Erika L FlanneryDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Nobutaka KatoBroad Institute, 415 Main Street, Cambridge MA 02142.
Olga TanaseichukThe Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA.
Eamon ComerBroad Institute, 415 Main Street, Cambridge MA 02142.
Bin ZhouThe Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA.
Kelli KuhenThe Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA.
Yingyao ZhouThe Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA.
Didier LeroyMedicines for Malaria Venture (MMV), PO Box 1826, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland.
Stuart L SchreiberBroad Institute, 415 Main Street, Cambridge MA 02142; Department of Chemistry and Chemical Biology, Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA.
Christina A SchererBroad Institute, 415 Main Street, Cambridge MA 02142.
Joseph VinetzDivision of Infectious Disease, Department of Medicine, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Elizabeth A WinzelerDivision of Pharmacology and Drug Discovery, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA. Electronic address: ewinzeler@ucsd.edu.

Funding

Sugar-feeding behavior of the malaria vector Nyssorhynchus darlingi and development of effective attractive toxic sugar baits (ATSB) to increase intervention success in PeruU19AI089681 · NIAID · YALE UNIVERSITY · PI CASTRO, MARCIA C. · 2010 to 2023
$20.1M
Discovery of chemically validated malaria liver stage targetsR01AI090141 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2011 to 2019
$3.4M
Defining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6M
NIAID NIH HHS R01 AI090141NIAID NIH HHS R01AI090141NIAID NIH HHS R01 AI103058NIAID NIH HHS R01AI103058NIAID NIH HHS U19 AI089681
6 · The paper itself

Abstract

Preventing transmission is an important element of malaria control. However, most of the current available methods to assay for malaria transmission blocking are relatively low throughput and cannot be applied to large chemical libraries. We have developed a high-throughput and cost-effective assay, the Saponin-lysis Sexual Stage Assay (SaLSSA), for identifying small molecules with transmission-blocking capacity. SaLSSA analysis of 13,983 unique compounds uncovered that >90% of well-characterized antimalarials, including endoperoxides and 4-aminoquinolines, as well as compounds active against asexual blood stages, lost most of their killing activity when parasites developed into metabolically quiescent stage V gametocytes. On the other hand, we identified compounds with consistent low nanomolar transmission-blocking activity, some of which showed cross-reactivity against asexual blood and liver stages. The data clearly emphasize substantial physiological differences between sexual and asexual parasites and provide a tool and starting points for the discovery and development of transmission-blocking drugs.

Indexed as

AntimalarialsDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansMalariaPlasmodium falciparumAntimalarialschemotherapygametocytesmalariaPlasmodiumtransmission

Identifiers

PMID26749441
PMCPMC4723716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.